Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Open Access
- 25 July 2022
- journal article
- editorial
- Published by Wiley in European Journal of Immunology
- Vol. 52 (9) , 1523-1526
Abstract
The known YAP inhibitor verteporfin is capable of repressing IL-17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17-mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (VI562/7‐1)
This publication has 9 references indexed in Scilit:
- Yap suppresses T-cell function and infiltration in the tumor microenvironmentPLOS Biology, 2020
- AhR–ROR‐γt complex is a therapeutic target for MAP4K3/GLK high IL‐17A high subpopulation of systemic lupus erythematosusThe FASEB Journal, 2019
- Non-canonical Hippo signaling regulates immune responses2019
- YAP Is Essential for Treg-Mediated Suppression of Antitumor ImmunityCancer Discovery, 2018
- A Hippo in the Fox(p3) houseNature Immunology, 2017
- The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cellsNature Immunology, 2017
- YAP/TAZ at the Roots of CancerCancer Cell, 2016
- Cutting Edge: The Pathogenicity of IFN-γ–Producing Th17 Cells Is Independent of T-betThe Journal of Immunology, 2013
- Inhibition of Autophagosome Formation by the Benzoporphyrin Derivative VerteporfinJournal of Biological Chemistry, 2011